Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 10 - 11 tags : Pharma save search
Pharma Microbiology Testing Kits Global Market to Reach $7.94 Billion by 2026 at an 8.8% CAGR
Published: 2022-10-11 (Crawled : 18:00) - prnewswire.com
QGEN | $39.31 -0.91% 240K
|
Health Technology
|
| O: -1.46%
H: 0.47%
C: -0.39%
ABT | $109.02 0.12% 1.7M
|
Health Technology
|
| O: -0.28%
H: 1.88%
C: 0.89%
QGEN | $39.31 -0.91% 240K
|
Health Technology
|
| O: -1.46%
H: 0.47%
C: -0.39%
NEOG P | $12.085 0.62% 520K
|
Health Technology
|
| O: -0.91%
H: 2.0%
C: -2.67%
BRKR | $84.0 -2.04% 180K
|
Health Technology
|
| O: -0.48%
H: 3.18%
C: 1.07%
pharma global market
Zealand Pharma major shareholder announcement: Polar Capital
Published: 2022-10-11 (Crawled : 15:20) - globenewswire.com
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
| Email alert
Add to watchlist
pharma
aTyr Pharma Announces Research Collaboration with Dualsystems Biotech AG to Identify 10 New Therapeutic Targets
Published: 2022-10-11 (Crawled : 14:20) - biospace.com/
LIFE | $1.65 -2.94% 130K
|
Health Technology
|
| O: 0.18%
H: 0.92%
C: -1.82%
pharma research collaboration biotech
Cocrystal Pharma Selects CDI-988 for Clinical Development as an Oral Treatment for COVID-19
Published: 2022-10-11 (Crawled : 14:00) - biospace.com/
COCP | $1.4079 2.1K
|
Health Technology
|
| O: -9.02%
H: 9.2%
C: 0.0%
cdi-988 covid-19 treatment pharma
UroGen Pharma to Host Thought Leader Webinar on UGN-102 and Non-Muscle Invasive Bladder Cancers
Published: 2022-10-11 (Crawled : 12:20) - biospace.com/
URGN | $14.88 -1.46% 43K
|
Health Technology
|
| O: -0.19%
H: 1.6%
C: 1.32%
ugn-102 pharma bladder cancer
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with Amgen’s LUMAKRAS® (sotorasib)
Published: 2022-10-11 (Crawled : 12:00) - globenewswire.com
BMY | $48.35 -0.33% 2.1M
|
Health Technology
|
| O: 0.12%
H: 2.63%
C: 1.59%
BBIO | $25.61 -0.62% 150K
|
Health Technology
|
| O: 1.06%
H: 3.53%
C: 0.95%
AMGN | $264.99 -0.2% 410K
|
Health Technology
|
| O: 3.16%
H: 4.59%
C: 2.48%
bbp-398 lumakras fda designation lung pharma trial cancer fast track designation
Novo Seeds Portfolio Company NMD Pharma Reports Positive Top-Line Phase I/IIa Data in Myasthenia Gravis
Published: 2022-10-11 (Crawled : 10:00) - prnewswire.com
NVO | $123.64 -0.21% 1.4M
|
Health Technology
|
| O: -0.25%
H: 1.95%
C: 0.77%
pharma seeds positive
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
TPET | $0.503 117.66% 21M
|
n/a
WISA 4 | $3.22 84.0% 56M
|
Electronic Technology
SXTC | $2.56 82.86% 11M
|
Health Technology
PRSO | $1.99 56.69% 52M
|
Manufacturing
PALI | $6.5 56.25% 22M
|
Manufacturing
JAGX | $0.1767 48.74% 430M
|
Health Technology
DYNT | $0.5255 41.87% 18M
|
Health Technology
MCBC | $13.795 38.92% 820K
|
Finance
BTTR | $6.86 34.51% 5.2M
|
Manufacturing
SNGX | $0.51 32.09% 6.3M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.